Description |
1 online resource (320 p.) |
Contents |
Front cover -- Half title -- Full title -- Copyright -- Dedication -- Contents -- Contributors -- Preface -- Chapter 1 -- Dementia and neurodegenerative disorder: An introduction -- 1.1 Introduction -- 1.2 Dementia -- 1.3 Etiology intended for dementia -- 1.3.1 Alzheimer's disease -- 1.3.2 Cerebrovascular disease -- 1.3.3 Huntington's disease -- 1.3.4 Parkinson's disease -- 1.3.5 Creutzfeldt-Jakob disease -- 1.3.6 Cerebral contusion -- 1.4 Genetic effects -- 1.5 Age -- 1.6 Physical activity -- 1.7 Comorbidity -- 1.8 Drugs -- 1.9 Psychometric symptoms |
|
1.10 Pathophysiology of neurodegenerative disorder -- AD -- 1.10.1 Amyloid beta peptide -- 1.10.2 Tau proteins -- 1.10.3 Heat shock protein -- 1.11 Pathogenesis of Parkinson's disease -- 1.12 Pathogenesis of vascular dementia -- 1.13 Pathogenesis of Huntington's disease -- 1.14 Treatment of neurodegenerative disorders -- 1.14.1 Alzheimer's disease -- 1.14.2 Parkinson's disease -- 1.14.3 Huntington's disease -- 1.14.4 Creutzfeldt-Jakob disease -- 1.14.5 New drug targets for dementia -- 1.14.6 Miscellaneous treatment -- 1.15 Blood-brain barrier |
|
1.16 Structure of blood-brain barrier -- 1.17 Tight junction involved in BBB -- 1.18 Features of endothelial and specialized cells forming BBB -- 1.19 Mechanisms to permeate the blood-brain barrier -- 1.19.1 Transcellular pathway -- 1.19.2 Paracellular pathway -- 1.19.3 Clathrin-mediated endocytosis -- 1.19.4 Carrier-mediated pathway -- 1.19.5 Receptor-mediated transport -- 1.19.6 Blood-brain barrier models -- 1.19.6.1 In vitro blood-brain barrier models -- 1.19.6.2 Micro blood-brain barrier models -- 1.19.6.3 Several advantages of using this model |
|
1.19.6.4 Immortalized rat brain cell lines -- 1.19.7 In vivo studies -- 1.19.8 Nanomedicine a therapeutic approach for neurodegenerative disorders and corresponding dementia -- 1.19.8.1 Nanomedicine for neurodegenerative diseases -- 1.20 Conclusion -- Conflict of interest -- Consent -- Acknowledgments -- References -- Chapter 2 -- Dementia: A journey from cause to cure -- 2.1 Introduction -- 2.2 Types of dementia -- 2.3 Alzheimer's disease -- 2.4 Etiopathogenesis -- 2.5 Lewy body dementia -- 2.6 Etiopathogenesis -- 2.7 Vascular dementia -- 2.8 Etiopathogenesis |
|
2.9 Frontotemporal dementia -- 2.10 Etiopathogenesis -- 2.11 Current treatments and drugs under clinical investigations -- 2.12 Conclusion -- References -- Chapter 3 -- Receptor attacking ligands for active targeting to brain -- 3.1 Introduction -- 3.2 Receptor-mediated nanocarrier platforms for brain drug delivery -- 3.2.1 Insulin receptor -- 3.2.2 Transferrin receptor -- 3.2.3 Folate receptor -- 3.2.4 Lipoprotein receptor -- 3.2.5 Leptin receptor -- 3.2.6 Nicotinic-acetylcholine receptors -- 3.2.7 Scavenger receptor -- 3.2.8 Interleukin receptors -- 3.3 Conclusion -- References |
|
Chapter 4 -- Dendrimers in the effective management of Alzheimer's and dementia |
Notes |
Description based upon print version of record |
Genre/Form |
Electronic books
|
Form |
Electronic book
|
Author |
Kesharwani, Prashant
|
ISBN |
9780323859066 |
|
0323859062 |
|